Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.

PIK3CA-positive breast cancer in postmenopausal women ID1401 Technology appraisal guidance TBC Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced ...

潜在“first-in-class”抗体偶联药物telisotuzumab vedotin有望获批治疗c-Met蛋白过度表达的经治局部晚期或转移性非鳞状NSCLC成人患者。 诺和诺德（Novo Nordisk ...